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esponsibility of Xi'aAbstract Liquid chromatography tandem mass chromatography (LC–MS/MS) is an important hyphenated
technique for quantitative analysis of drugs in biological ﬂuids. Because of high sensitivity and selectivity,
LC–MS/MS has been used for pharmacokinetic studies, metabolites identiﬁcation in the plasma and urine.
This manuscript gives comprehensive analytical review, focusing on chromatographic separation
approaches (column packing materials, column length and mobile phase) as well as different acquisition
modes (SIM, MRM) for quantitative analysis of glucocorticoids and stimulants. This review is not meant
to be exhaustive but rather to provide a general overview for detection and conﬁrmation of target
drugs using LC–MS/MS and thus useful in the doping analysis, toxicological studies as well as in
pharmaceutical analysis.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.sity. Production and hosting by Elsev
5
59681, +91 11 26059688x5647,
8874.
mail.com,
n Jiaotong University.1. Introduction
Corticosteroids and stimulants are the class of compounds that are
illicitly used by professionals owing to their anti-inﬂammatory
and mood elevating as well as euphoric properties respectively.
They are widespread abused among sports persons [1], stimulant
addiction among teenagers and deliberate counterfeiting in herbal
products to enhance their effects [2,3]. Hence there is a need for
more sensitive analytical tools to detect and conﬁrm these classes
of drugs in biological ﬂuids [3,4]. These analytical tools would
serve to fulﬁll demands in forensic, toxicological and food safety
departments. Glucocorticoid belongs to steroid family, particularlyier B.V. All rights reserved.
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have important functions upon carbohydrate, protein and calcium
metabolism, potent anti-inﬂammatory and immunosuppressive
activities [5–8]. The activity of glucocorticoids largely depends
upon the substituent attached to the nucleus. Substituent has been
found to signiﬁcantly increase both glucocorticoids and miner-
alocorticoids activities. It has been found that Δ1, 2 corticosteroids
enhance anti-inﬂammatory activity and decrease salt retaining
activity [9]. Some selected glucocorticoids and their structures
are shown in Table 1. Stimulants are the class of drugs that have a
marked effect on mental function and behavior, producing
euphoria and reduced fatigue. They are diverse class of com-
pounds that exhibit their action through different mechanism.
This class of drugs is often abused by teenagers leading to
addiction and risk of health hazards. Some of selected stimulants
are modaﬁnil, famprofazone, tuaminoheptane, amiphenazole,
amphetamine, methamphetamine, dimethylamphetamine, methyl-
phenidate, 3,4-methylene-dioxy-N-amphetamine, 3,4-methylene-
dioxy-N-ethylamphetamine, strychnine and 3,4-methylene-dioxy-
N-methamphetamine etc.
Thus there is need for sophisticated and robust analytical
strategy to conﬁrm their presence in biological ﬂuids. A number
of different analytical approaches are available for this purpose.Table 1 General nucleus of corticoids and different substitutions of
.
Steroid name Δ1, 2 R6 R9 R
Hydrocortisone Saturated –H –H –
Cortisone Saturated –H –H Q
Corticosterone Saturated –H –H –
Fludrocortisone Saturated –H –F –
Prednisolone Double bond –H –H –
Prednisone Double bond –H –H Q
Methylprednisolone Double bond ––CH3 –H –
Prednisolone acetate Double bond –H –H –
Dexamethasone Double bond –H –F –
Betamethasone Double bond –H –F –
Beclomethasone Double bond –H –Cl –
Triamcinolone Double bond –H –F –
Triamcinolone acetonide Double bond –H –F –Analytical techniques such as high performance liquid chromato-
graphy (HPLC), ultra high performance liquid chromatography
(UHPLC), mass spectrometry, gas chromatography, electrochemi-
cal detection and enhanced conﬁrmatory procedures are used in
detection of these classes of drugs. Recent development and
advancement in analytical technologies has emerged with more
sophisticated hyphenated techniques, to detect nanograms of drugs
or their metabolites in biological ﬂuids. Among hyphenated
techniques, LC–MS/MS is the choice of interest because it is
highly sophisticated and considerably powerful tool for detection
of low and high molecular weight analytes. New methods have
enabled the determination of drugs that were formerly difﬁcult to
detect by conventional methods of analysis as well as time
consuming procedures have been replaced by faster, more
comprehensive and robust assays. Good sensitivity and high
throughput are key factors for the LC–MS/MS approaches used
in drug analysis.
In this review, we present an overview of the methodologies that
are reported in literature for detection, conﬁrmation of corticosteroids
and stimulants in biological ﬂuids. Reported screening methods using
LC–MS/MS approach highlight chromatographic separation and
different modes of instrumental acquisition (selective ion monitoring
(SIM), multiple reaction monitoring (MRM), precursor ion scan) fordifferent glucocorticoids drugs.
11 R16 R17 R21
–OH –H ––OH ––OH
O –H ––OH ––OH
–OH –H –H ––OH
–OH –H ––OH ––OH
–OH –H ––OH ––OH
O –H ––OH ––OH
–OH –H ––OH ––OH
–OH –H ––OH ––OCOCH3
–OH (á isomer) ––OH ––OH
–OH (â isomer) ––OH ––OH
–OH (â isomer) ––OH ––OH
–OH ––OH ––OH ––OH
–OH ––OH
Table 2 Selected conﬁrmatory methods for detecting glucocorticoids in biological ﬂuids.
Analyte Matrix Pretreatment Column; mobile phase Detection
mode
LOD Ref.
9 Synthetic
corticosteroids
Urine LLE with
Extrelut-
NT3
columns
Inertsil ODS-3 C18 column
(150 mm 3 mm, 3 μm); 1 mM
ammonium acetate pH 6.8/ACN (60:40,
v/v) at 0.4 mL/min
ESI negative
SIM mode
1 ng/mL [12]
20 Corticosteroids Urine Enzymatic
hydrolysis
C-8 SCX
SPE
Cartridge
Supelcosil LC-8-DBcolumn
(2.1 mm 3.3 cm, 3 μm); 5 mM acetic
acid/10 mM ammonium acetate (pH 3.8)/
methanol, at 0.2 mL/min
ESI positive
MRM
0.1–10 ng/mL [13]
Methylprednisolone
methylprednisolone
acetate
Plasma Protein
precipitation
Sinergy Max RP C-12 column
(2.0 mm 150 mm, 4 μm); 0.01%
formic acid in water/ACN (50:50, v/v) at
0.2 mL/min
ESI positive
MRM
6–300 ng/mL [14]
17 Synthetic
glucocorticoids
Urine Enzymatic
hydrolysis
followed by
LLE
BEH C18 column(2.1 mm 50 mm,
1.7 μm); 0.1% formic acid in ACN/0.1%
formic acid in water, at 0.35 mL/min
TOF-MS with
ESI positive
0.1–3.3 μg/L [15]
Methylprednisolone Methylprednisolone
Plasma
LLE Pursuit C-18 column (2.0 mm 150 mm,
5 μm); ACN/0.5% formic acid aq.
solution (85:15, v/v) at 0.2 mL/min
ESI positive
SRM
20–2000 ng/
mL
[16]
5 Corticosteroids:
dexamethasone,
ﬂumethasone,
ﬂuorometholone,
beclomethasone,
triamcinolone acetonide
Urine Enzymatic
hydrolysis
Oasis-HLB
SPE column
Alltima C-18 column (2.1 mm × 150
mm, 5 µm); ACN/water(40:60, v/v) at
0.3 mL/min
APCI positive
SRM mode
2–3 ng/mL [17]
Cortisol, cortisone,
prednisolone,
prednisone
Plasma Protein
precipitation
Zorbax-SB phenyl, HT rapid resolution
column (2.1 mm 100 mm, 1.8 μm);
ACN/H2O/ formic acid(32:68:0.1, v/v) at
0.140 mL/min
APCI positive
MRM mode
0.5–2 ng/mL [18]
Prednisone, prednisolone,
dexamethasone, cortisol
Human serum SPE Symmetry C-18 column
(2.1 mm 30 mm, 3.5 μm); methanol/
5 mM acetate buffer pH 3.25 at 400 μL/
min
ESI negative
MRM mode
0.2–0.5 ng/mL [19]
Cortisol, dexamethasone,
prednisone,
prednisolone,
methylprednisolone
Plasma SPE Oasis
HLB
Cartridge
Symmetry C-18 column
(2.1 mm 30 mm, 3.5 μm); 5 mM
ammonium acetate buffer pH 3.5 and
methanol (95:5, v/v)/methanol and 5 mM
ammonium acetate buffer pH 3.5 (95:5,
v/v), at 400 μL/min
ESI negative
MRM mode
3–7 ng/mL [20]
21 Synthetic
corticosteroids
Urine Enzymatic
hydrolysis
followed by
LLE
RP DB-8 column (4.6 mm 75 mm,
3 μm); 1% acetic acid/ methanol, at
1 mL/min
APCI positive
full scan mode
5 ng/mL [21]
Cortisol, cortisone,
prednisolone,
dexamethasone,
11-deoxycortisol
Plasma, urine saliva,
plasma-ultra ﬁltrate
SPE Oasis
HLB 1 cm3
Cartridge
Acquity UPLC BEH C-18 column
(2.1 mm 50 mm, 1.7 μm); A¼2 mM
ammonium acetate in water with 0.1%
formic acid, B¼2 mM ammonium
acetate in methanol with 0.1% formic
acid, at 0.4 mL/min, total run time 3 min.
ESI positive
MRM
0.6–5 nM [22]
16 Glucocorticoids Urine Enzymatic
hydrolysis
followed by
LLE
Halo C-18 column(2.1 mm 150 mm,
2.7 μm and 2.1 mm 100 mm, 2.7 μm);
water with 0.1% formic acid/ACN with
0.1% formic acid at 400 μL/min
ESI positive
MRM
5–15 ng/mL [23]
15 Synthetic
glucocorticoids
Urine Enzymatic
hydrolysis
followed by
LLE
Zorbax C-18 column (2.1 mm 50 mm,
1.8 μm); 0.1% acetic acid/ACN with
0.1% acetic acid at 0.3 mL/min
ESI positive
MRM
1–30 ng/mL [24]
14 Glucocorticoids Urine Enzymatic
hydrolysis
followed by
LLE
Inertsil ODS-3 C18 column
(50 mm 4.6 mm, 3 μm); 1% formic
acid/ACN, at 700 μL/min
ESI positive
MRM
1–5 ng/mL [25]
Ref.—References.
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Table 3 Selected conﬁrmatory methods for detecting stimulants in biological ﬂuids.
Analyte Matrix Pretreatment Column; Mobile phase Detection mode LOD Ref.
9 Stimulants including
strychnine,
methylphenidate,
amiphenazole,
famprofazone,
tuaminoheptan
Urine Enzymatic
hydrolysis
followed by LLE
Halo C-18 column (2.1 mm
 150 mm, 2.7 μm and
2.1 mm 100 mm, 2.7 μm); water
with 0.1% formic acid/ACN with
0.1% formic acid at 400 μL/min
ESI positive
MRM
70–300
ng/mL
[23]
Mesocarb, modaﬁnil,
formoterol
Urine Enzymatic
hydrolysis
followed by LLE
Zorbax C-18 column
(2.1 mm 50 mm,1.8 μm); 0.1%
acetic acid/ACN with 0.1% acetic
acid at 0.3 mL/min
ESI positive
MRM
100–200
ng/mL
[24]
Methylphenidate, mesocarb Urine Enzymatic
hydrolysis
followed by LLE
Inertsil ODS-3 C18 column
(50 mm 4.6 mm, 3 μm); 1%
formic acid/ACN, at 700 μL/min
ESI positive
MRM
5 ng/mL [25]
49 Stimulants Urine Enzymatic
hydrolysis SPE
cartridge
Phenomex Luna C-18 column( 2 mm
 100 mm, 3 μm); 5 mM
ammonium acetate with 0.1% formic
acid/ ACN, at 0.3 mL/min
ESI positive 0.025 μg/mL [26]
27 Amphetamine and
amphetamine like drugs
Urine LLE Omnispher C-18 column
(3.0 mm 50 mm, 3 μm); 0.1%
formic acid/methanol, at 0.4 mL/min
APCI positive full
scan MS
1–25 ng/mL [27]
7 Amphetamine derivatives:
AP, MA, MDA, MDMA,
MDEA, DMA, DMANO
Urine Oasis HLB SPE Capcell C-18 MG-II column
(2.0 mm 150 mm, 5 μm); 5 mM
ammonium formate pH 4.0/ACN, at
230 μL/min
ESI positive
MRM
1.95 ng/mL [28]
Mesocarb Urine Enzymatic
hydrolysis
followed by LLE
Thermo-Hyper Gold C-18
(2.1 mm 50 mm, 3 μm ); 15 mM
ammonium formate containing 1%
formic acid/ACN at 200 μL/min
SRM positive 5 ng/mL [29]
AP, MA, MDA, MDMA,
MDEA, PMA, ephedrine
Urine LLE Acquity UPLC HSS C-18 column
(2.1 mm 100 mm, 1.8 μm ); 5 mM
ammonium formate buffer
containing 0.05% formic acid/
methanol, at 0.3 mL/min
ESI positive
MRM
0.5–2.5
ng/mL
[30]
AP: amphetamine, MA: methamphetamine, MDA: 3,4-methylenedioxy-N-amphetamine, DMA: N, N-dimethylamphetamine, PMA: p-hydroxy-
methamphetamine, MDMA: 3,4-methylenedioxy-N-methamphetamine, MDEA: 3,4-methylenedioxy-N-ethylamphetamine, DMANO: N, N-dimethyl
amphetamine-N-oxide, SPE: solid phase extraction, LLE: liquid–liquid extraction, ACN: acetonitrile, Ref: references.
Table 4 Empirical formula, exact masses, MS fragmentation data, Log P and λmax of selected glucocorticoids and stimulants.
Drug name Empirical
formula
Exact mass [M+H]+ m/z of major
fragments reported
Log Pa λmax (nm) Ref.
Amphetamine C9H13N 135.10480 136.2 119.2, 91.2 1.8 257, 263 [28]
MDA C10H13NO2 179.09463 180.2 163, 134.9, 105 1.64 233, 285 [28,30]
MDMA C11H15 NO2 193.11028 194.1 163.2, 105.1 2.15 234, 285 [28,30]
Beclomethasone C22H29ClO5 408.17035 409.18 391, 373, 337 2.03 239 [17,24]
Betamethasone C22H29FO5 392.19990 393 337, 355, 241, 147 1.94 240 [24,25,35–37]
Budesonide C25H34O6 430.23554 431 413, 341, 323, 173 2.18 248 [24,32,36,37]
Dexamethasone C22H29FO5 392.19990 393 373, 355, 337, 237, 147 1.83 240 [17,24,35–37]
Fludrocortisone C21H29FO5 380.19990 381 343, 239 1.67 240 [24,36]
Flumethasone C22H28F2O5 410.19047 411 371, 335, 253, 121 1.9 238 [17,24,32,35]
Fluocortolone C22H29FO4 376.20499 377 321, 303 2.1 242 [24]
Methylphenidate C14H19NO2 233.14158 234 174, 129, 84, 56 0.20 264 [23,25,35]
Methylprednisolone C22H30O5 374.20932 375 357, 339, 161 1.82 240 [16,25,36,37]
Prednisolone C21H28O5 360.19367 361 343, 325, 147, 307 1.62 240 [24,25,35–37]
Prednisone C21H26O5 358.17802 359 341, 323, 267, 147, 34 1.46 240 [24,25,35–37]
Strychnine C21H22N2O2 334.16813 335 264, 184, 156 1.9 255 [21,23]
Triamcinolone C21H27FO6 394.17917 395 357, 321, 225 1.16 238 [24,25,36,37]
Triamcinolone C24H31FO6 434.21047 435 415, 397, 213 1.2 238 [24,25,36,37]
Acetonide
aValues obtained from online SRC Phys Prop Database, Ref.—References.
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Table 5 Characteristics fragment ions of glucocorticoids
obtained in ESI negative mode LC–MS/MS.
Analyte m/z fragments
Cortisone 329.2a, 301.2, 311.2
Dexamethasone 361.2a, 307.2, 325.2
Hydrocortisone 331.2a, 297.2, 282.2
Flumethasone 379.2a, 325.2, 305.2
Flunisolide 375.2a, 357.2, 433.2
Methylpednisolone 343.2a, 309.2, 294.2
Prednisolone 329.2a, 295.2, 280.2
Prednisone 327.2a, 299.2, 285.2
Triamcinolone 345.2a, 325.2, 393.2
Triamcinolone acetonide 413.2a, 337.2, 375.2, 469.2
aIndicate base peak.
Quantitative analysis of glucocorticoids and stimulants 345MS detection. Proposed mass fragmentation pathways of selected
drugs are incorporated in this review.2. Screening methods for detection of glucocorticoids and
stimulants in biological ﬂuids using liquid chromatography
mass spectrometry
LC–MS/MS techniques provide speciﬁc, selective and sensitive
quantitative results with reduced sample preparation. Other tech-
niques such as electrochemical detection were also explored for
the analysis of drugs. Goyal et al. [10,11] investigated electro-
chemical behavior of dexamethasone and triamcinolone at the
fullerene-C60-modiﬁed pyrolytic graphite electrode (PGE) using
Osteryoung square wave voltammetry (SWV) and they illustrated
quantitative determination of dexamethasone and triamcinolone in
several commercially available pharmaceutical formulations and
human blood plasma of patients being treated with dexametha-
sone. LC–MS/MS is currently most ideal tools for screening and
quantifying corticosteroids in biological ﬂuids as compared to
other conventional techniques. This technique is widely used for
pharmacokinetic (PK) studies, metabolites identiﬁcation in plasma
and urine, doping analysis and forensic studies. The introduction
of commercial hyphenated instruments in which liquid chromato-
graphy is coupled with different mass analyzers such as time of
ﬂight mass spectrometry (LC–TOFMS), triple quadrupole mass
spectrometer and soft ionization techniques [electrospray ioniza-
tion (ESI), atmospheric pressure chemical ionization (APCI),
atmospheric pressure photo ionization (APPI), and matrix assisted
laser desorption ionization (MALDI) etc.] has simpliﬁed the
laboratory analysis and also decreased the cost of analysis to
some extent. The polarity and functionalities of corticosteroids and
stimulants allow the use of ionization techniques in positive ion or
negative ion modes and different modes of instrumental acquisi-
tion for mass detection. Tables 2 and 3 summarize the information
on methods used for identiﬁcation and conﬁrmation of corticos-
teroids [12–25] and selected stimulants [26–30].
Fluri et al. [12] reported conﬁrmatory method for 11 corticos-
teroids in urine samples based on LC–ESI–MS. The selective and
sensitive method for conﬁrmation and identiﬁcation of nine
synthetic corticosteroids assured the exclusion of false positive
results obtained by corticosteroid group ELISA screening tests.
Emmie et al. [13] developed two high throughput LC–MS
methods for the screening of anabolic steroids, corticosteroids,
and acidic drugs using a high efﬁciency LC column coupled with afast scanning triple quadrupole mass spectrometer. The detection
of 40 anabolic steroids, corticosteroids, and 52 acidic drugs were
achieved within a 6.5 min and a 4.5 min LC–MRM run, respec-
tively and all the targets were detected at low amount. Validation
data showed that both methods have acceptable precision to be
used on a routine basis and no interference from sample matrix
was observed.
A rapid, sensitive and speciﬁc method for the simultaneous
detection and quantization of methylprednisolone acetate (MPA)
and methylprednisolone (MP) in rat plasma, using a triple stage
quadrupole was developed and validated by Panusa et al. [14]
using LC–ESI–MS/MS. Its excellent applicability in PK studies
was demonstrated. It was proved to be highly sensitive, allowing
detection and quantization of the analytes at lower concentrations.
Method was developed by Touber et al. [15] using the latest
high-resolution LC column technology, UPLC™, and ESI inter-
face in the positive ion mode. Gradient UPLC separation condi-
tions were optimized for a group of 22 analytes including 17
glucocorticosteroids. The UPLC–TOF–MS separation obtained
required 5.5 min only for all the substances tested. Even the
critical pair of dexamethasone and betamethasone isomers was
almost completely resolved. The authors recommended that
dedicated UPLC–TOF–MS criteria regarding the number of
identiﬁcation points (IPs), mass accuracy of parent, fragment ions,
ion ratio, and relative retention time have not been assessed, in
order to allow application of this new technology for conﬁrmation
of identity as well, that should be considered and thus needs
improvement.
Mazzarino et al. [23] performed screening of several classes of
substances in a single chromatographic method with a run-time of
11 min, inclusive of post-run and reconditioning times. The
effectiveness of this approach was evaluated by LC–ESI–MS/
MS in the positive mode, using 20 blank urine samples spiked
with 45 compounds prohibited in sport including 16 glucocorti-
coids and 9 stimulants. All of the analytes were clearly distin-
guishable in urine, with limits of detection ranging from 5 ng/mL
to 350 ng/mL. All the compounds of interest were separated,
including synthetic and endogenous glucocorticoids with similar
retention times and fragmentation patterns.
Kolmonen et al. [26] developed a general screening method
based on solid phase extraction (SPE), LC–TOF/MS and validated
124 different doping agents including stimulants in urine. The
result indicated that compared with conventional doping control
methods, this method was more ﬂexibility in identiﬁcation,
database management and reduced the time required for analysis.
A selective and sensitive method for the qualitative screening of
urine samples for 27 amphetamine and amphetamine-type drugs
was described by Deventer et al. [27] using mass spectrometer
equipped with APCI interface, operated in positive ionization
mode. They reported that the amount of urine routinely used in
their laboratory for the extraction of these stimulants (5 mL) was
reduced to 2 mL and thus reduced sample volume. The detection
limits for all the compounds were lower than 25 ng/mL except for
chlorphentermine, thus it was good alternative to gas chromato-
graphy with nitrogen phosphorus detector (GC-NPD).
Kim et al. [28] developed and validated LC–ESI–MS/MS
method for the simultaneous detection and quantiﬁcation of seven
amphetamine derivatives amphetamine (AP), methamphetamine
(MA), 3,4-methylenedioxy-N-amphetamine (MDA), 3,4-methyle-
nedioxy-N-methamphetamine (MDMA), 3,4-methylenedioxy-N-
ethylamphetamine (MDEA), N,N-dimethylamphetamine (DMA)
and N,N-dimethylamphetamine-N-oxide (DMANO) in human
Fig. 4 Proposed mass fragmentation pathway of strychnine drug. 1—
Molecular ion peak at M+¼335. 2—Base ion peak at m/z¼264.
3—Daughter ion peak at m/z¼156.
Fig. 1 Proposed mass fragmentation pathway of dexamethasone
drug. 1—Molecular ion peak at M+¼393. 2—Base ion peak at m/
z¼373. 3—Daughter ion peak at m/z¼355.
Fig. 2 Proposed mass fragmentation pathway of prednisolone drug. 1
—Molecular ion peak at M+¼361. 2—Base ion peak at m/z¼343.
3—Daughter ion peak at m/z¼307.
Fig. 3 Proposed mass fragmentation pathway of prednisone drug. 1
—Molecular ion peak at M+¼359. 2—Base ion peak at m/z¼341.
3—Daughter ion peak at m/z¼171.
J. Haneef et al.346urine. The paper reported that the SPE step was assayed to detect
and quantify seven target analytes in urine samples without any
signiﬁcant interference from the matrix components.
Counterfeiting of herbal drugs with synthetic agents can also be
detected by LC–MS/MS [31,32]. Different mass analyzers (TOF,
IT (ion trap)) have been coupled with LC and extensively used for
screening and characterization of different analytes in plasma and
herbal extracts [33,34].3. Focusing on different strategies for detection of
glucocorticoids and stimulants in biological ﬂuids
Based on the reported MS-fragmentation data, a common frag-
mentation could be developed in screening of corticosteroids and
stimulants. The basic information regarding empirical formula,
exact masses, Log P and absorption maxima (λmax) is also
summarized in Table 4. P and Log P are partition coefﬁcient or
logarithm of the partition coefﬁcient of a drug. These parameters
express the relative distribution of drug between oil and water
under speciﬁed conditions for example, octanol/water at 37 1C andpH 7.4. Drugs with higher P or Log P are more lipophilic,
generally distribute more rapidly and to a greater degree into
bodily tissues and ﬂuids. These physicochemical properties help in
prediction of drug transport. These data render to presume
interaction of analyte with stationary phase, thereby allowing a
good evaluation of its chromatographic performance. UV spectra
can help as a preliminary screening to distinguish different
analytes on the basis of their absorption maxima (λmax).
The super-imposable nature of UV spectra of an analyte with a
certiﬁed reference material (CRM) can give fair idea about their
structural similarity to much extent. This approach has been employed
for detection of adulteration using HPLC with UV detector.
The precursor and products ions summarized in Table 4, are
based on positive ionization. Depending upon the nature of target
analytes, ionization mode is optimized. Fluri et al. [12] studied
both negative and positive ionization modes for examined
glucocorticoids. Due to less fragmentation and a better signal-to-
noise ratio (4:1), sensitivity increased for measurements in the
negative ionization mode. They assessed that fragmentation of
corticosteroids in the ESI negative mode is simple as few ions
were produced. The products ions of ten selected corticosteroids
by their study are presented in Table 5.4. Proposed mass fragmentation pattern
The hypothetical mass fragmentation pattern of some selected
drugs like dexamethasone, prednisolone, prednisone and
Quantitative analysis of glucocorticoids and stimulants 347strychnine on the basis of MRM transitions has been incorporated
and that helps in conﬁrmation of analytes on the basis of
diagnostic ions (Figs. 1–4). The daughter ions generated from
the parent ions help to predict the fragmentation pattern of the
molecule and are useful in conﬁrmation of the target analytes.5. Conclusion
With the advancement of hyphenated techniques, high resolution
mass analyzers as well as high throughput separation approaches,
quantitative analysis of glucocorticoids and stimulants can be
achieved with good sensitivity. Newer methods can be developed
for routine analysis of target analytes in biological ﬂuids with
shorter run time and good detectability. Application of new fused
core columns for their effectiveness and use of both positive and
negative polarities in a single run need to explore.References
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